Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 5, 2008, Pages 633-639

  Baechler, Sébastien ^a,b   Hobbs, Robert F ^a   Prideaux, Andrew R ^a   Recordon, Mélanie ^b   Bischof Delaloye, Angelika ^b   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

90Y ibritumomab tiuxetan; Dosimetry; Kidney; Radioimmunotherapy

Indexed keywords

IBRITUMOMAB TIUXETAN;

ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL PRACTICE; DOSIMETRY; DRUG TUMOR LEVEL; HUMAN; KIDNEY; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY;

ANTIBODIES, MONOCLONAL; BODY WEIGHT; FEMALE; HUMANS; KIDNEY; KINETICS; NEOPLASMS; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOMETRY; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING; YTTRIUM RADIOISOTOPES;

EID: 55849089217     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0506     Document Type: Article

References (13)

1. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 2003;44:465.
2. 111In-labelled platelets in organs. Eur J Nucl Med 1982;7:80.
3. Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys 1994;21:1409.
4. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S.
5. Shen S, Forero A, LoBuglio AF, et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 2005;46:642.
6. Kojima A, Takaki Y, Matsumoto M, et al. A preliminary phantom study on a proposed model for quantification of renal planar scintigraphy. Med Phys 1993;20:33.
7. Buijs WC, Siegel JA, Boerman OC, et al. Absolute organ activity estimated by five different methods of background correction. J Nucl Med 1998;39:2167.
8. Berger MJ, Hubbell JH, Seltzer SM et al. XCOM: Photon Cross-Section Database (version 1.3). Available online at: http://physics.nist.gov/xcom Gaithersburg, MD: National Institute of Standards and Technology, 2005. Accessed on March 15, 2008.
9. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations, Revised Ed. New York: The Society of Nuclear Medicine, 1991.
10. Weber DA, Eckerman KF, Dillman LT, et al. MIRD: Radionuclide Data and Decay Schemes. New York: The Society of Nuclear Medicine, 1989.
11. 90Y-labeled ibritumomab tiuxetan therapy: Possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. Cancer Biother Radiopharm 2007;22:113.
12. Kasiske BL, Umen AJ. The influence of age, sex, race, and body habitus on kidney weight in humans. Arch Pathol Lab Med 1986;110:55.
13. 90Y-ibritumomab tiuxetan: Comparative dosimetric study for tailored treatment. J Nucl Med 2007;48:1871.